CO2019006926A2 - New T-cell receptors and immune therapy that uses them - Google Patents
New T-cell receptors and immune therapy that uses themInfo
- Publication number
- CO2019006926A2 CO2019006926A2 CONC2019/0006926A CO2019006926A CO2019006926A2 CO 2019006926 A2 CO2019006926 A2 CO 2019006926A2 CO 2019006926 A CO2019006926 A CO 2019006926A CO 2019006926 A2 CO2019006926 A2 CO 2019006926A2
- Authority
- CO
- Colombia
- Prior art keywords
- taa
- antigen recognition
- cell receptors
- nucleic acids
- new
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 3
- 238000009169 immunotherapy Methods 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 101100168911 Arabidopsis thaliana CUL4 gene Proteins 0.000 abstract 1
- 102000012698 DDB1 Human genes 0.000 abstract 1
- 102100025178 DDB1- and CUL4-associated factor 4-like protein 2 Human genes 0.000 abstract 1
- 101100168913 Dictyostelium discoideum culD gene Proteins 0.000 abstract 1
- 101100170004 Dictyostelium discoideum repE gene Proteins 0.000 abstract 1
- 101100170005 Drosophila melanogaster pic gene Proteins 0.000 abstract 1
- 101000721255 Homo sapiens DDB1- and CUL4-associated factor 4-like protein 2 Proteins 0.000 abstract 1
- 101100168914 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pcu4 gene Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 101150077768 ddb1 gene Proteins 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000009258 tissue cross reactivity Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención se relaciona con construcciones de reconocimiento de antígeno contra un antígeno asociado a tumor (TAA) derivado de la proteína blanco 2 similar al factor 4 asociado con DDB1 y CUL4 (DCAF4L2). La invención en particular provee nuevas moléculas basadas en receptores de células T (TCR) que son selectivas y especificas por el TAA de la invención. Los TCR de la invención, y los fragmentos de unión a TAA derivados de los mismos, son útiles para el diagnóstico, tratamiento y prevención de enfermedades cancerosas que expresan TAA. Además se proveen ácidos nucleicos que codifican para las construcciones de reconocimiento de antígeno de la invención, vectores que comprenden estos ácidos nucleicos, células recombinantes que expresan las construcciones de reconocimiento de antígeno y composiciones farmacéuticas que comprenden los compuestos de la invenciónThe present invention relates to antigen recognition constructs against a tumor associated antigen (TAA) derived from target protein 2 similar to factor 4 associated with DDB1 and CUL4 (DCAF4L2). The invention in particular provides new molecules based on T cell receptors (TCR) that are selective and specific for the TAA of the invention. The TCRs of the invention, and TAA-binding fragments derived therefrom, are useful for the diagnosis, treatment, and prevention of cancer diseases expressing TAA. Also provided are nucleic acids that encode the antigen recognition constructs of the invention, vectors that comprise these nucleic acids, recombinant cells that express the antigen recognition constructs, and pharmaceutical compositions that comprise the compounds of the invention.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662431580P | 2016-12-08 | 2016-12-08 | |
| DE102016123859.7A DE102016123859B3 (en) | 2016-12-08 | 2016-12-08 | New T cell receptors and their use in immunotherapy |
| PCT/EP2017/081893 WO2018104478A1 (en) | 2016-12-08 | 2017-12-07 | Novel t cell receptors and immune therapy using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019006926A2 true CO2019006926A2 (en) | 2019-09-18 |
Family
ID=67874111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0006926A CO2019006926A2 (en) | 2016-12-08 | 2019-06-27 | New T-cell receptors and immune therapy that uses them |
Country Status (6)
| Country | Link |
|---|---|
| CL (1) | CL2019001537A1 (en) |
| CO (1) | CO2019006926A2 (en) |
| IL (1) | IL267131A (en) |
| MY (1) | MY196025A (en) |
| NZ (1) | NZ754366A (en) |
| PH (1) | PH12019501263A1 (en) |
-
2017
- 2017-12-07 MY MYPI2019003103A patent/MY196025A/en unknown
- 2017-12-07 NZ NZ754366A patent/NZ754366A/en not_active IP Right Cessation
-
2019
- 2019-06-05 CL CL2019001537A patent/CL2019001537A1/en unknown
- 2019-06-05 IL IL267131A patent/IL267131A/en unknown
- 2019-06-06 PH PH12019501263A patent/PH12019501263A1/en unknown
- 2019-06-27 CO CONC2019/0006926A patent/CO2019006926A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2019001537A1 (en) | 2019-10-11 |
| IL267131A (en) | 2019-08-29 |
| NZ754366A (en) | 2022-02-25 |
| PH12019501263A1 (en) | 2020-01-20 |
| MY196025A (en) | 2023-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019006727A (en) | NEW T-CELL RECEPTORS AND IMMUNE THERAPY THAT USES THEM. | |
| MX2019006724A (en) | NEW T-CELL RECEPTORS AND IMMUNE THERAPY THAT USES THEM. | |
| CO2019006914A2 (en) | New t-cell receptors and immune therapy that uses them | |
| CL2020001181A1 (en) | New genetically modified T-cell receptors and immune therapies using them. | |
| MX395287B (en) | NEW T LYMPHOCYTE RECEPTORS AND IMMUNOTHERAPY BASED ON THEIR USE. | |
| EA201992131A1 (en) | HIGH-AFFINE SPECIFIC TO MAGE-A1 TCR AND THEIR APPLICATION | |
| MX2023003463A (en) | T cell receptors and immune therapy using the same against prame positive cancers. | |
| MY205262A (en) | Novel t cell receptors and immune therapy using the same | |
| PH12019500312A1 (en) | T cell receptors and immune therapy using the same | |
| MX2017012427A (en) | NOVELTY PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TUMORS. | |
| MX2017017148A (en) | NOVEDOUS PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOFAGIC CANCER AND OTHER CANCERES. | |
| BR112018006006A2 (en) | antigen receptors, peptide chains, recombinant cells, methods for producing a cell expressing an antigen receptor and for treating a disease, nucleic acids and pharmaceutical composition | |
| MX2020001287A (en) | Braf-specific tcrs and uses thereof. | |
| AR113834A1 (en) | GENETICALLY MODIFIED T-CELL RECEPTORS AND IMMUNE THERAPIES THAT USE THEM | |
| CO2019006926A2 (en) | New T-cell receptors and immune therapy that uses them | |
| NZ750479A (en) | T cell receptors and immune therapy using the same | |
| EA202090712A1 (en) | NEW GENETIC ENGINEERED T-CELL RECEPTORS AND IMMUNE THERAPY WITH THEIR USE | |
| AR110682A1 (en) | T-CELL RECEIVERS AND IMMUNE THERAPY USING THEM | |
| AR110504A1 (en) | T-CELL RECEIVERS AND IMMUNE THERAPY USING THEM | |
| EA201992002A1 (en) | T-CELL RECEPTORS AND IMMUNE THERAPY OF PRAME-POSITIVE CANCER DISEASES WITH THEIR APPLICATION | |
| EA201990488A1 (en) | NEW T-CELL RECEPTORS AND IMMUNOTHERAPY WITH THEIR APPLICATION | |
| BR112016030462A2 (en) | binding molecules, one or more isolated polynucleotides, one or more vectors, host cell, method of producing a binding molecule, pharmaceutical composition, use of the binding molecule, method of treating disease and inducing target cell lysis |